Catalyst Wire Dossier Catalyst Wire Dossier

ARO-APOC3 (Plozasiran)

ploza­siran · Arrowhead Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARO-APOC3 (Plozasiran), covering 2026-02-04 to 2026-02-04. Get the full timeline:

Most recent: Clinical Trial Update: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) [Phase 3]

See pricing